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Abstract 
Objective: Pilot trial comparing prism therapy and visual search training, for 
homonymous hemianopia, to standard care (information only). 
Methods: Prospective, multicentre, parallel, single-blind, three-arm RCT across 
fifteen UK acute stroke units. 
Participants: Stroke survivors with homonymous hemianopia. 
Interventions: Arm a (Fresnel prisms) for minimum 2 hours, 5 days/week over 6-
weeks. Arm b (visual search training) for minimum 30 minutes, 5 days/week over 6-
weeks. Arm c (standard care-information only).  
Inclusion criteria: Adult stroke survivors (>18 years), stable hemianopia, visual acuity 
better than 0.5logMAR, refractive error within ±5Dioptres, ability to read/understand 
English, and provide consent.  
Outcomes: Primary outcomes were change in visual field area from baseline to 26 
weeks and calculation of sample size for a definitive trial. Secondary measures 
included Rivermead Mobility Index, Visual Function Questionnaire 25/10, Nottingham 
Extended Activities of Daily Living, Euro Qual, Short Form-12 questionnaires and 
Radner reading ability. Measures were post-randomisation at baseline and 6, 12, 26 
weeks. 
Randomisation: Randomisation block lists stratified by site and partial/complete 
hemianopia. 
Blinding: Allocations disclosed to patients. Primary outcome assessor blind to 
treatment allocation. 
Results: 87 patients were recruited: 27 - Fresnel prisms, 30 – visual search training 
and 30 - standard care. 69% male; mean age 69 years (SD 12). At 26 weeks, full 
results for 24, 24 and 22 patients respectively were compared to baseline. Sample 
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size calculation for a definitive trial determined as 269 participants per arm for a 200 
degree2 visual field area change at 90% power. Non-significant relative change in 
area of visual field was 5%, 8% and 3.5% respectively for the three groups. Visual 
Function Questionnaire responses improved significantly from baseline to 26 weeks 
with visual search training (60 (SD19) to 68.4 (SD20)) compared to Fresnel prisms 
(68.5 (SD16.4) to 68.2 (18.4): 7% difference) and standard care (63.7 (SD19.4) to 
59.8 (SD22.7): 10% difference), p=0.05. Related adverse events were common with 
Fresnel prisms (69.2%; typically headaches).  
Conclusions: No significant change occurred for area of visual field area across arms 
over follow-up. Visual search training had significant improvement in vision-related 
quality of life. Prism therapy produced adverse events in 69%. Visual search training 
results warrant further investigation.  
The trial is funded by the UK Stroke Association. Trial Registration: Current 
Controlled Trials ISRCTN05956042. 
 
Keywords: Homonymous hemianopia; Pilot trial;  Prism therapy; Randomised 
controlled trial; Standard care; Stroke; Visual search training 
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Introduction 
Homonymous hemianopia results in loss of one half of the visual field in both eyes 
[1,2]. The reported prevalence of visual field loss following stroke has been as high 
as 63% [3] in hospital populations although estimates vary widely as the proportion 
testing positive is highly dependent on time post stroke. Visual field defects can 
seriously impact functional ability and quality of life following stroke [4,5]. Patients 
with visual field defects have an increased risk of falling [6], impaired ability to read, 
poor mood and institutionalization [6-9]. Visual field loss may impact on a patient`s 
ability to participate in rehabilitation, and may ultimately result in poor long term 
recovery [8]. Visual field loss can result in accidents or injuries which have 
subsequent cost implications to the NHS and the patient [10]. 
Two key interventions commonly used in the clinical setting to improve vision in 
hemianopia are visual search compensatory training and provision of prisms [11]. A 
Cochrane systematic review [11] evaluated the interventions for homonymous 
hemianopia and found evidence in favour of visual search training. Subsequently, 
Aimola and colleagues [12] conducted a trial of visual search training for 
homonymous hemianopia and reported evidence of improved quality of life in the 
intervention group. The Cochrane review did not find sufficient evidence for prisms 
as an intervention for hemianopia.  
The aim of this pilot trial was to to compare  visual rehabilitation interventions with 
NHS standard care, in patients with hemianopia following stroke. We wished to 
explore whether visual rehabilitation was more effective than standard care (advice 
only) at improving functional outcome in patients with hemianopia following stroke, 
and whether prism therapy or visual search therapy was more effective at improving 
functional outcome in patients with hemianopia following stroke. 
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Methods 
Trial design 
VISION was a randomised controlled, multicentre pilot trial with NHS research 
ethical approval (10/H1003/119). The trial protocol is reported elsewhere [13].  
Participants 
Patients were eligible for inclusion if they met the criteria: 
a. 18 years of age or older; 
b. Best corrected visual acuity of 0.5 or better in each eye at distance; 
c. Stable homonymous hemianopia (partial or complete) induced by recent stroke, 
defined following WHO guidelines, present over 2 weeks (to exclude rapid recovery 
cases) but less than 26 weeks prior to randomisation;  
d. Refractive error within ±5Dioptres; 
e. Willing and able to give consent for the study; 
f. Prior to stroke able to read and understand English. 
 
Patients were not eligible for inclusion if they were: 
a. unable to consent due to severe cognitive impairment; 
b. assessed to have ocular motility impairment and/or visual inattention in addition to 
the visual field impairment; or 
c. had pre-existent visual field impairment due to previous stroke. 
 
Participants were recruited from stroke units based in 15 United Kingdom (UK) 
National Health Service (NHS) Trusts.  Potentially eligible participants were identified 
by stroke research nurses, and screened for inclusion by a local principal 
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investigator (a qualified orthoptist registered with the health and Care Professions 
Council, UK). Participants eligible for inclusion, and providing consent, attended for a 
baseline assessment, which included assessment and documentation of patient 
demographics, visual signs and symptoms, visual acuity measures, any additional 
ocular problems, comorbidity, severity of stroke and level of disability.   
 
Recruitment and randomisation 
Participants were individually randomised to one of three treatment groups using a 
secure (24-hour) web based randomisation programme. Randomisation lists were 
generated using block randomisation stratified by centre and degree of hemianopia 
(partial or complete) with treatment allocation ratio of 1:1:1. The local PI (orthoptist) 
obtained the treatment allocation and subsequently assigned the participant to the 
treatment arm. 
 
Interventions 
Treatment A: Fresnel prisms 
Participants were assessed and given sector Fresnel prisms of 40 prism dioptre 
strength on their glasses (or plain glasses if not already worn) [14]. Separate prism 
segments were used as a mechanical displacement to expand the upper and lower 
quadrants. Full fitting details are detailed in the protocol [13]. Participants were 
advised to wear the prisms for a minimum of 2 hours daily, for a minimum six weeks, 
from prism affixation; after this they could elect to continue treatment if wished.  
Treatment B: Visual search training 
Participants were assessed and provided with visual search training. This comprised 
an A4 landscape card with horizontal and diagonal numbered circles radiating out 
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from a central fixation target. Full instructions for training are detailed in the protocol 
[13]. Participants were instructed to continually scan between the various targets for 
30 minutes daily for a minimum six weeks, after which they could elect to continue 
treatment if they wished. Participants were instructed on the search exercises to 
ensure their understanding of doing this training. In addition, printed instructions 
were provided with the visual training target cards.  
Treatment C: Control - Standard Care (Information Only) 
Participants were given information leaflets from the UK Stroke Association and the 
UK Royal National Institute for the Blind (RNIB) about visual impairment following 
stroke.  
 
Participants in all treatment groups received these information leaflets. Details of 
usage of the prisms and visual search training were collected by diaries, completed 
daily by participants.  
 
Outcomes 
Outcomes were assessed at baseline, 6, 12 and 26 weeks. The primary clinical 
outcome was relative change in visual field area (measured in degrees2) from 
baseline to 26 weeks and, based on this change, a sample size calculation for a 
future definitive trial. Secondary clinical outcomes, assessed by the orthoptist, were 
reading ability (speed and accuracy). Secondary clinical outcomes, reported by 
patients, were assessed through questionnaire booklets. [13].  Further key objectives 
of this pilot trial were to test the operationalisation of the intervention and the study 
outcome measures [13, 15].   
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Sample size calculation 
A sample size calculation was estimated for repeated measures analysis of 
covariance [16], using the data generated on visual field assessment.  
 
Visual field assessment 
A blinded qualified Orthoptist assessed visual field area. An Esterman strategy was 
used for quantitative visual field assessment with standard fixation monitoring 
strategies of fixation loss, false positive and false negative responses. This was done 
using either: 
• The Esterman programme on Humphrey or Octopus perimetry, 
• The III4e target on Goldmann with additional checks of static points in the 
central visual field. 
A template for Goldmann perimetry was supplied for standardisation to match the 
Esterman strategy on Humphrey and Octopus perimetry. A binocular visual field was 
measured first followed by monocular assessment of the right and left eyes. Visual 
fields were performed without prisms in place in the Fresnel prism arm. Where it was 
not possible to use either of these methods then the standardised confrontation 
method was used. Whichever method used at baseline was repeated at every follow 
up visit. Where the confrontation method was used at baseline one of the above 
quantitative methods was used at the follow-up if possible in addition to repeating the 
confrontation method. 
 
Reading Ability 
Reading ability, assessed using the Radner reading test, is reported as time taken to 
read (seconds) and number of incorrect words from the 14 word passage [17]. 
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Patient Completed Outcome Measures 
Participants completed a questionnaire booklet containing the following outcome 
measures: 
a. Visual function questionnaire (VFQ 25-10) [18] 
b. Rivermead mobility index (RMI) [19] 
c. Nottingham extended activities of daily living assessment (NEADL) [20] 
d. Euro Qual [21] 
i. 5D (EQ-5D) 
ii. VAS score (EQ-VAS) 
e. Short Form -12 (SF-12) [22] 
 i. Physical component summary (PCS) 
 ii. Mental component summary (MCS) 
 
 
Statistical Analysis 
There were insufficient data to carry out a formal power calculation to determine 
sample size for this trial, a sample size of 105 participants was considered sufficient 
to reach pilot objectives [13].  
 
Outcome data were analysed according to the intention-to-treat principle. Safety 
analyses included all patients were randomised to and received treatment. A p-value 
of 0.05 is considered significant, however as this is a pilot study not powered to 
identify differences, results will be interpreted with caution. Additionally, rather than 
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adjust for multiplicity relevant results from other studies will be taken into account in 
the interpretation of results.  
 
The statistical analysis plan, written by the trial statisticians and agreed by other 
members of the trial management group (TMG) and independent oversight 
committees: data and safety monitoring committee (IDSMC) and the trial steering 
committee (TSC), prior to any comparative analyses together is available on request 
from the authors. No imputation methods were used for missing data and all patients 
who withdrew from the trial were encouraged to complete follow up. 
 
All analyses were done with SAS software version 9.2. The primary feasibility 
outcome of sample size calculation was calculated for a repeated measures analysis 
of covariance [16]. Data collected from the trial were used to estimate the standard 
deviation, estimate of correlation and the loss to follow up rate for the main trial. All 
outcomes were summarised using descriptive statistics, split by treatment, at 
baseline and 26 week follow up. The primary efficacy outcome was relative change 
in area of visual field assessment (VFA), defined as the difference in VFA from 
baseline to 26 weeks follow up, divided by the maximum possible VFA score for 
each method, and was analysed using ANOVA, controlling for treatment. A 
sensitivity analysis was performed on the VFA using ANCOVA for the modal 
assessment method (see Outcomes – Visual Field Assessment). Patient reported 
secondary outcomes: VFQ 25-10; RMI; NEADL; EQ-VAS and SF-12: PCS and MCS, 
reported at 26 week follow up, were compared using analysis of covariance, 
controlling for treatment and baseline assessment. EQ-5D and Radner Reading 
Score were summarised using only descriptive statistics,   
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Results 
Recruitment and characteristics 
Recruitment and screening have been reported elsewhere [23). In summary, 1171 
patients were assessed for eligibility between 17th May 2011 and 9th September 
2013. Of these, 993 patients (84.8%) did not meet the inclusion criteria, 91 patients 
declined to participate (7.8%) leaving 87 patients in the study (7.4%). The reasons 
for not being eligible and for refusing to consent were recorded and published [23]. 
In May 2012, the team noted that the proportion of eligible patients was lower than 
expected and this was slowing recruitment. Upon reviewing the accumulating 
recruitment data, the IDSMC recommended extending recruitment by one year and 
advised that the initial target sample size of 105 be reduced to 90 participants, of 
which 60 would be needed to complete the study. The TSC agreed with this proposal 
and the TMG actioned this amendment in June 2012. Figure 1 shows the cumulative 
recruitment graph, indicating expected, revised expected and actual recruitment by 
month.  
At the end of the recruitment period, 27, 30 and 30 patients were randomised to 
Fresnel prisms, Visual search training and standard care respectively. Two  patients 
(2/87, 2.3%) withdrew from data analysis and follow up; nine (9/87, 10.3%) from 
follow up only and  five (5/87, 5.7%) were lost to follow up, of which four were from 
the standard arm (4/5, 80.0%). There was 24 (24/27, 88.9%), 25 (25/30, 83.3%) and 
22 (22/30, 73.3%) patients in the Fresnel prisms, Visual search training and standard 
care respectively at 26 week follow up (see Figure 2).  
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Patient demographic and clinical characteristics at baseline are provided in Table 1 
and 2. There were no notable differences at baseline between three arms. The 
population consisted primarily of white (97.6%) males (69.4%) randomised, on 
average, 11 weeks post ischaemic (95.3%) stroke (late recruitment relating to the 
requirement for stable, non-recovering hemianopia).. The infarct was mostly 
classified unilateral (43.5% left; 54.1% right).  
 
Sample size outcome 
Table 3 provides the sample size needed per arm to detect a minimally clinically 
important difference in visual field between per arm for a given power. Predictions 
are provided for three values of the minimally clinically important difference (200, 400 
and 600 degrees2) and for three levels of power (90%, 80% and 50%). 80% (70/87) 
of patients had full data at baseline and 26 weeks. Thus the required number of 
patients to be recruited was calculated as 1.25 times (=1/0.8) the sample size shown 
in Table 3. Most recruiting sites used the Humphrey Static methods, with 33 in 70 
(47.1%) patients having their VFA assessed using this method. Computing the 
sample size in the same way for patients being assessed by this method only 
reduces the number required (Table 3). 
 
Primary clinical outcome 
There was some variability in baseline relative change in visual field area across 
treatment arm and by method (Table 4), particularly those methods used most 
frequently. For the Humphrey Static Esterman method, the mean baseline visual 
field area was one-third lower in the standard care arm (955.8 degrees) when 
compared to the visual search training or Fresnel prism arm; 1428.9 degrees and 
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1382.5 degrees respectively. For the Octopus Static Esterman method, the mean 
baseline visual field was 44.2% and 18.4% higher in the standard care arm when 
compared to the visual search training and Fresnel prism arm respectively. These 
differences can be explained by the large within-group variances of visual field  
expected with a relatively low sample size per method of assessment and per arm. 
The mean values of relative change in visual field area are given in Table 5, which 
shows a non-significant average minimal increase in visual field at 26 weeks of 5%, 
8% and 3.5% for Fresnel prisms, Visual search training and standard care, 
respectively (p-values >5%, <5% and >5%, respectively).  
 
Secondary clinical outcomes 
Change in functional activity was evaluated as a secondary analysis. Visual function 
(using the VFQ 25-10) improved at 26 weeks in the visual search training arm (60 
(SD19) to 68.4 (SD20) when compared to the Fresnel Prisms (68.5 (SD16.4) to 68.2 
(18.4) and standard care arms ((63.7 (SD19.4) to 59.8 (SD22.7): Table 6, ANCOVA 
p=0.05). No evidence of differences across arms were found for any of the other 
secondary outcomes, including functional mobility (ANCOVA p=0.36, extended daily 
level index (ANCOVA p=0.93), EQ-5D VAS score (ANCOVA p=0.60), change of 
general health status (ANCOVA p=0.51), reading speed and reading accuracy. 
 
Compliance 
There were 73 protocol deviations in 58 patients (68.2% overall: 77% in the Fresnel 
prism arm, 93% in the visual search arm and 34.5% in the standard care arm). The 
majority of deviations (n=41, 56.2%) related to lack of compliance in the intervention 
arms (e.g., prism not worn a minimum of 2 hours daily for 6 weeks or visual 
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exercises not carried out for 30 minutes daily for 6 weeks). Compliance level was 
similar across the intervention arms. Patients in the Fresnel prisms arm wore the 
prisms during 27 days on average, and patients in the visual search training arm 
followed the visual search exercises 28 days on average. The protocol deviations in 
the standard group (n=10) were all related to timing and attendance at follow up 
visits. 
Eighteen patients (69.2%) in the Fresnel prisms arm experienced a total of 42 
adverse events  of which 28 were classified as headache (Table 7). Two patients 
(6.7%) in the visual search training arm experienced seven  adverse events (6 
fatigue, 1 headache). No adverse events were recorded for in the standard care arm.  
Continuation of treatment was greater in the visual search arm than in the Fresnel 
prisms arm. In the visual search arm, 24 of 25 patients continued the intervention 
after 6 weeks, 21 of 25 after 12 weeks and 10 of 25 patients after 26 weeks. This 
was in comparison to 14 of 26 patients in the Fresnel prism arm after 6 weeks, 12 of 
23 after 12 weeks and 5 of 24 patients after 26 weeks.  
 
Discussion  
Our primary clinical outcome measure was based on formal quantitative visual field 
assessment. Because of the multi-centre nature of the trial, a variety of visual field 
assessment methods were used as different hospitals had access to different 
perimeters. For future phase III trials using multiple visual field assessment methods, 
our sample size estimation is a maximum of 269 participants per arm for a minimum 
clinically important difference of 200 degree2 of visual field area relative change. 
Future trials using just one visual field assessment method require a sample size of 
a maximum of 132 participants for each arm.  
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The primary clinical outcome measure for this trial was relative change in visual field 
area from baseline to 26 weeks. A Cochrane systematic review of interventions for 
post-stroke visual field loss concluded that, generally, interventions for homonymous 
hemianopia did not result in improvement of visual field [11]. Our results similarly 
showed minimal non-significant change in visual field across all 3 arms of 5, 8 and 
3.5%. We considered that a change of 15% in visual field area would be clinically 
significant. The insignificant change in visual field was expected given the deliberate 
recruitment ofdenoting the stable hemianopes recruited to the trial. Other trials 
recruiting stable hemianopias also report no significant change to extent of visual 
field loss [12,24]. 
Published evidence relating to the effectiveness of interventions for post-stroke 
visual field loss is limited. Pollock and colleagues [11] concluded from their 
systematic review that compensatory scanning training interventions may be more 
beneficial than a placebo or control intervention at improving specific tasks. More 
recently, Aimola and colleagues [12] conducted a randomised controlled trial of 
visual exploration versus sham training and reported significant improvement in 
vision-related quality of life questionnaire scores following the intervention in 
comparison to sham training. They found no significant objective improvement noted 
in activity of daily living tasks. Our secondary clinical outcome measures included a 
range of questionnaires and indices to measure vision-related and health-related 
quality of life and activities of daily living. The only outcome measure to show a 
statistically significant change was vision-related quality of life (VFQ25/10).  
Pollock and colleagues [11] found insufficient evidence to reach conclusions about 
the effectiveness of prisms; one more recent trial [24] compared real versus sham 
prism training. Their analysis of mobility questionnaire results showed no significant 
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different in real versus sham prism use. Our data showed no significant difference in 
motility questionnaire results. However, we noted a range of adverse events related 
to treatment which were greatest for the Fresnel prism arm (69.2%) versus the visual 
search training arm (6.7%). There were no adverse events for standard care.  
Evaluation of recruitment and consent has been conducted for this trial and 
published previously [23]. We experienced greater recovery for hemianopia than 
previously reported in the literature and this should be taken into consideration when 
planning future trials with options to increase number of participating recruitment 
centres.  
Adverse events reported with Fresnel prism therapy included headaches, difficulties 
with navigation, double vision, optical glare/aberrations and visual confusion, similar 
to events reported in previous trials [14,24]. Headaches were the most common 
adverse event for Fresnel prisms. We acknowledge that headaches can also be a 
post-stroke symptom. However, in this trial, given that headaches were not a 
symptom reported by patients receiving standard care and uncommon in those 
receiving visual search training, they were attributed to the Fresnel prism treatment. 
Given the extent and range of adverse events reported with prism wear, caution 
must be exercised if prescribing prism glasses as an intervention for homonymous 
hemianopia.  
Adverse events for visual search training were minimal and consisted of fatigue and 
headache. To help minimise these potential side effects training periods should be 
curtailed to shorter accumulated periods rather than one long training session. 
We used treatment diaries to capture patient use of interventions and extracted data 
from these and the case report forms as to whether patients voluntarily chose to 
continue their intervention beyond the minimum set treatment period of 6 weeks. 
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More patients in the visual search arm voluntarily opted to continue their intervention 
than patients in the Fresnel prism arm. 
We noted 73 protocol deviations. For the intervention arms, these largely related to 
compliance with the treatment duration although no significant difference was found 
in the level of compliance in both intervention arms. In future trials participants could  
be encouraged to break up their treatment duration per day as also suggested for 
reduction of adverse events; for example of having 3 shorter blocks of treatment per 
day instead of only one large block of treatment. For standard care most deviations 
related to follow-up visits taking place outside the time windows stipulated by the 
protocol. When planning future trials consideration should be given to regular 
telephone contact with patients to encourage on-going compliance with treatment 
and with timely reminders of upcoming review visits. This may also help with 
reducing loss to follow-up cases. 
 
Considerations 
A potential limitation of the trial was the need to use different visual field perimeters, 
and perimetrists, across recruitment sites for the primary outcome visual field 
measurements. A consideration in future trials would be to use just one perimeter 
type or consider alternative primary outcome measures. Given that visual fields did 
not change significantly and requires patients to attend follow-up appointments at 
hospital eye clinics (a potential deterrent to trial participation) an appropriate 
alternative primary outcome measure may be a vision-related quality of life 
questionnaire such as the VFQ25 although there are many other questionnaires to 
choose from dependent on whether a health-related or condition-specific 
questionnaire is required [25].  
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With regard to generalizability, as this is a pilot trial, results should be interpreted 
with caution [265]. Although we found a statistically significant improvement in 
VFQ25 for visual search training, our trial was not powered for this. Nonetheless, the 
clinical differences are encouraging and warrant further investigation.  
There remains insufficient evidence to reach conclusions about whether prisms are 
an effective intervention, and this study provides evidence of a high rate of adverse 
events associated with prism use. Clinicians with expert knowledge relating to prisms 
may consider their use for individual patients, but clinicians and patients both should 
be fully aware of potential adverse events and have a clear understanding relating to 
prism use. 
 
Conclusions 
Our visual search training or Fresnel prism interventions for hemianopia produced 
minimal change in visual field area over the 26-week follow-up period. Visual search 
training produced a significant improvement in vision-related quality of life but not for 
other activity of daily living tasks. There were no significant improvements for any 
quality of life measure in our Fresnel prism arm. For the visual search arm, our 
participants reported a low percentage of adverse events, many continued with 
training and we found a significant change in quality of life. This must be interpreted 
with caution given our low sample size  
There are a number of considerations in relation to planning future trials. Assessing 
change in visual field which required formal visual field assessment using a variety of 
perimeter types. It would help to limit assessment to one method or alternatively 
remove this as an outcome measure. We experienced low recruitment initially but 
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took measures to improve this with increased number of recruitment centres and met 
the revised target for recruitment.  
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Figure 1. Cumulative recruitment graph for all centres 
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Figure 2. CONSORT 2010 Flow Diagram 
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Table 1. Baseline demographic characteristics 
 
 
 
 Treatment  
Baseline Characteristic Fresnel 
prisms 
Visual 
search 
training 
Standard 
care 
Total 
Patients Randomised 26 30 29 85 
Age (years) 
Mean (SD), median (IQR), 
range 
 
69.9  (12.9) 
68.8 (14.4) 
35.2 to 
90.2 
 
70.9  
(11.2) 
72.9 (15.2) 
40.5 to 
89.3 
 
66.2  
(11.3) 
68.2 (16.2) 
42.8 to 
85.6 
 
69.0  (11.8) 
69.0 (15.3) 
36.2 to 90.2 
Gender,  
        Male, n (%) 
 
22 (84.6) 
 
17 (56.7) 
 
20 (69.0) 
 
59 (69.4) 
Ethnicity   
        White n, (%) 
        Black n, (%) 
        Asian n, (%) 
        Mixed n, (%) 
 
25 (96.1)  
1 (3.9)  
0 (0.0)   
0 (0.0)  
 
30 (100.0)  
0 (0.0)  
0 (0.0)   
0 (0.0)  
 
28 (96.6)  
1 (3.4)  
0 (0.0)   
0 (0.0)  
 
83 (97.6)  
2 (2.4)  
0 (0.0)   
0 (0.0)  
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 Treatment  
Baseline Characteristic Fresnel prisms Visual search 
training 
Standard 
care 
Total 
Patients Randomised 26 30 29 85 
Stroke onset (days from stroke to randomisation)  
Mean (SD) 
Median (IQR) 
Range 
 
75.5  (45.3) 
64.5 (78.0) 
18.00 to 173.0 
 
73.8  (49.2) 
69.0 (97.0) 
13.0 to 172.0 
 
81.2  (48.0) 
67.0 (61.0) 
15.0 to 186.0 
 
76.9  (47.2) 
67.0 (77.0) 
13.0 to 186.0 
Stroke Type  
Ischaemic, n (%) 
Haemorrhagic, n (%) 
 
25 (96.2)  
1 (3.8)  
 
28 (93.3)  
2 (6.7)  
 
28 (96.6)  
1 (3.4)  
 
81 (95.3)  
4 (4.7)  
Side of infarct  
Left, n (%) 
Right, n (%) 
Bilateral, n (%) 
 
9 (34.6)  
16 (61.5)   
1 (3.9) 
 
17 (56.7)  
13 (43.3)   
0 (0.0) 
 
11 (37.9)  
17 (58.6)   
1 (3.5) 
 
37 (43.5)  
46 (54.1)   
2 (2.4) 
Visual field assessment diagnosis: 
 Homonymous hemianopia left partial, n (%) 
 Homonymous hemianopia right partial, n (%) 
 Homonymous hemianopia left complete, n (%) 
 Homonymous hemianopia right complete, n (%) 
 Bilateral hemianopia, n (%) 
 
8 (30.8)  
3 (11.5)   
9 (34.6)  
6 (23.1)   
0 (0.0) 
 
5 (16.7)  
9 (30.0)   
8 (26.7)  
8 (26.7)   
0 (0.0) 
 
8 (27.6)  
5 (17.2)   
10 (34.5)  
6 (20.7)   
0 (0.0) 
 
21 (24.7)  
17 (20.0)   
27 (31.8)  
20 (23.5)   
0 (0.0) 
Barthel index score 
Mean (SD) 
Median (IQR) 
Range  
 
97.5  (5.5) 
100.0 (0.0) 
80.0 to 100.0 
 
92.7  (11.9) 
100.0 (15.0) 
65.0 to 100.0 
 
93.3  (14.7) 
100.0 (5.0) 
45.0 to 100.0 
 
94.4  (11.6) 
100.0 (5.0) 
45.0 to 100.0 
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Table 3. Sample size estimation – total number of patients with complete follow up required per arm (significance level= 
0.05) 
 
  Type II error (β) 
  0.1 0.2 0.5 
Estimated using data from  all visual field assessment methods 
Minimally clinically 
important difference 
200 degrees2 269 203 98 
400 degrees2 68 51 25 
600 degrees2 30 23 11 
Estimated using data from  modal visual field assessment method: Humphrey 
Minimally clinically 
important difference 
200 degrees2 132 100 48 
400 degrees2 33 25 12 
600 degrees2 15 12 6 
Page 31 of 41
Acta Neurologica Scandinavica - PROOF
Acta Neurologica Scandinavica - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PROOF
 
 
 
Page 32 of 41
Acta Neurologica Scandinavica - PROOF
Acta Neurologica Scandinavica - PROOF
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
PROOF
 
 
Table 4. Descriptive statistics for visual field by group, time-point and assessment method  
 
A: Baseline Treatment  
Timepoint 
Perimetry method (degrees2) 
Statistic 
Fresnel prisms 
 
(N=26) 
Visual search training 
(N=30) 
Standard care 
 
(N=29) 
Total 
 
(N=85) 
Baseline 
Confrontation 
n 
mean (sd) 
missing 
Humphrey Static Esterman 
n 
mean (sd) 
missing 
Goldmann Kinetic Esterman 
n 
mean (sd) 
missing 
Octopus Static Esterman 
n 
mean (sd) 
missing 
Octopus Kinetic Esterman 
n 
mean (sd) 
missing 
Other 
n 
Not done 
N 
 
 
0 
NA 
NA 
 
13 
1382.5  (1190.3) 
 0 
 
2 
779.5  (1102.4) 
0 
 
11 
1858.5  (1547.8) 
0 
 
0 
NA 
NA 
 
0 
 
0 
 
 
1 
0.0  (NA) 
0 
 
14 
1428.9  (942.1) 
0 
 
5 
922.4  (1600.4) 
0 
 
9 
1525.4  (1169.9) 
0 
 
0 
NA 
NA 
 
1 
 
0 
 
 
0 
NA 
NA 
 
12 
955.8  (840.8) 
0 
 
4 
894.3  (1541.9) 
0 
 
13 
2199.7  (1504.8) 
0 
 
0 
NA 
NA 
 
0 
 
0 
 
 
1 
0.0  (NA) 
0 
 
39 
1267.9  (1000.3) 
0 
 
11 
886.2  (1364.7) 
0 
 
33 
1902.1  (1419.9) 
0 
 
0 
NA 
NA 
 
1 
 
0 
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B: 26 week follow up 
assessment 
Confrontation 
n 
mean (sd) 
missing 
Humphrey Static Esterman 
n 
mean (sd) 
missing 
Goldmann Kinetic Esterman 
n 
mean (sd) 
missing 
Octopus Static Esterman 
n 
mean (sd) 
missing 
Octopus Kinetic Esterman 
n 
mean (sd) 
missing 
Not done 
n 
 
 
 
0 
NA 
NA 
 
13 
1743.5  (1419.6) 
0 
 
2 
1153.5  (686.6) 
0 
 
9 
1738.4  (1498.2) 
0 
 
0 
NA 
NA 
 
2 
 
 
 
1 
3126.0  (NA) 
0 
 
11 
1542.2  (778.9) 
0 
 
5 
1792.4  (1940.3) 
0 
 
8 
1897.6  (1527.3) 
0 
 
0 
NA 
NA  
 
5 
 
 
 
0 
NA 
NA 
 
10 
1165.8  (958.6) 
0 
 
2 
1736.5  (2160.2) 
0 
 
10 
2101.3  (1514.0) 
0 
 
0 
NA 
NA 
 
5 
 
 
 
1 
3126.0  (NA) 
0 
 
34 
1508.5  (1104.5) 
0 
 
9 
1638.0  (1612.7) 
0 
 
27 
1920.6  (1461.6) 
0 
 
0 
NA 
NA 
 
14 
 
0 represents complete homonymous hemianopia 
6262 is the maximum visual field area score representing a normal hemifield 
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Table 5. Relative change in visual field  
 
A: by treatment group  
     95% Confidence Interval for 
Mean 
 N Mean Std. 
Deviation 
Std. Error Lower 
bound 
Upper bound 
Fresnel prisms 24 0.05247973 0.13958788 0.02849326 -0.00646 0.11142 
Visual search training 24 0.08152371 0.14880363 0.03037441 0.01869 0.14436 
Standard care 22 0.0352049 0.15023043 0.03202924 -0.03140 0.10181 
Total 70 0.0570084 0.1453011 0.0173668 0.02236 0.09165 
 
 
B:  ANOVA results for relative change in visual field (comparison across arms) 
 
Source Sum of squares DF Mean 
Square 
F-test P-
value 
Treatment 0.02537506 2 0.01268753 0.59 0.5551 
Error 1.43138058 67 0.02136389   
Corrected total 1.45675564 69    
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Table 6 VFQ outcome assessment 
 
A: Descriptive statistics by group and time-point 
 
 Treatment  
Timepoint 
     Statistic 
Fresnel 
prisms 
 
(26) 
Visual search 
training 
(N=30) 
Standard care 
 
(N=29) 
Total 
 
(N=85) 
Baseline 
n 
mean (sd) 
median (IQR) 
(min, max) 
Not done 
 
25 
68.5  (16.4) 
71.2 (62.1 to 
76.9) 
(19.8, 93.9) 
1 
 
 
30 
60.0  (19.0) 
56.4 (44.5 to 
78.8) 
(21.2, 96.0) 
0 
 
28 
63.7  (19.4) 
63.2 (44.6 to 
77.2) 
(35.0, 93.0) 
1 
 
 
83 
63.8  (18.5) 
64.4 (47.0 to 
77.7) 
(19.8, 96.0) 
2 
 
26 follow-up 
assessment 
n 
mean (sd) 
median (IQR) 
(min, max) 
Not done 
 
24 
68.2  (18.4) 
70.1 (57.1 to 
84.7) 
(18.2, 96.5) 
2 
 
 
25 
68.4  (20.0) 
73.4 (53.5 to 
83.0) 
(25.5, 99.2) 
5 
 
19 
59.8  (22.7) 
63.9 (38.2 to 
79.4) 
(22.9, 95.2) 
10 
 
 
68 
65.9  (20.3) 
68.9 (53.2 to 
85.6)) 
(18.2, 99.2) 
17 
 
 
B: Analysis of Covariance (ANCOVA) results for changes in VFQ scores 
across arms  
 
Patients who do not have VFQ data for baseline and/or 26 week follow up were not 
included  
 
Source Sum of squares DF Mean Square F-test P-value 
Baseline score 13368.70569 1 13368.70569 65.05 <0.0001 
Treatment 1294.77789 2 647.38895 3.15 0.0497 
Error 12947.44855 63 205.51506   
Corrected total 27610.93214 66    
 
Parameter Estimates 
 
Variable Estimate Standard 
Error 
t-value P-value 
Intercept 10.0277624
6 
6.92848157 1.45 0.1528 
Baseline score 0.80599816 0.09875501 8.16 <0.0001 
Visual Search 
Training 
10.4170670
4 
4.36870996 2.38 0.0201 
Fresnel Prism 2.86798670 4.49330209 0.64 0.5256 
Standard Care 0.00000000 . . . 
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Table 7. Adverse events across groups  
 
Adverse event Fresnel prisms 
 
(N=26) 
Visual search 
training 
(N=30) 
Standard care 
 
(N=29) 
Event  Events: 
n 
Patients: 
n(%) 
Events: 
n 
Patients: 
n(%) 
Events: 
n 
Patients: 
n(%) 
Difficulty with 
navigation 
2 2 (7.7) 0 0 (0.0) 0 0 (0.0) 
Diplopia 5 5 (19.2) 0 0 (0.0) 0 0 (0.0) 
Dizziness 2 1 (3.8) 0 0 (0.0) 0 0 (0.0) 
Fatigue 0 0 (0.0) 6 1 (3.3) 0 0 (0.0) 
Headache 28 6 (23.1) 1 1 (3.3) 0 0 (0.0) 
Optical 
glare/aberrations 
1 1 (3.8) 0 0 (0.0) 0 0 (0.0) 
Visual confusion 4 3 (11.5) 0 0 (0.0) 0 0 (0.0) 
Total 42 18 (69.2) 7 2 (6.7) 0 0 (0.0) 
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Figure 1: Achievement of recruitment numbers per month of recruitment period. Blue 
denotes expected recruitment while orange denotes the revised expected 
recruitment and grey for actual recruitment. 
Figure 2: Flow diagram depicting stages of trial as per CONSORT reporting 
guidelines. 
Table 1: Baseline demographic characteristics for total trial and per group. 
Table 2: Baseline clinical characteristics for total trial and per group. 
Table 3: Outcome measure of sample size estimation determined if all visual field 
assessment methods were used in a future trial or if only Humphrey visual field 
assessment was used. 
Table 4: Visual field results descriptive statistics for total trial and per group. 
Table 5: Outcome measure of relative change in visual field area by treatment group 
and across groups. 
Table 6: Outcome measure of VFQ25 questionnaire results for total trial and per 
group. 
Table 7: Outcome measure of adverse events reported for each group. 
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CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 2-3 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3-4 
2b Specific objectives or hypotheses 4 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons n/a 
Participants 4a Eligibility criteria for participants 5 
4b Settings and locations where the data were collected 5-6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
 
6-7 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
 
7 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a 
Sample size 7a How sample size was determined 8 
7b When applicable, explanation of any interim analyses and stopping guidelines n/a 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 5 
8b Type of randomisation; details of any restriction (such as blocking and block size) 5-6 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
 
 
5 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
 
5, 8 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those  
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CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 6 
11b If relevant, description of the similarity of interventions n/a 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 9 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 9-10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
 
11 
13b For each group, losses and exclusions after randomisation, together with reasons 11 
Recruitment 14a Dates defining the periods of recruitment and follow-up 11 
14b Why the trial ended or was stopped 11 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 11 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
 
11 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
 
12-13 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended n/a 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
 
12-13 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 13-14 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 17 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 14-15 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 14-16 
Other information  
Registration 23 Registration number and name of trial registry 3 
Protocol 24 Where the full trial protocol can be accessed, if available 4 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 3, 18 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
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